The mild side effect profile and the ability to provide sulforaphane-containing BSE, for example, as a ‘functional food’ could make it an attractive option for individuals with prediabetes and MARD characteristics, whereas other treatment modalities, including intensive lifestyle intervention programmes or drugs that specifically target high insulin resistance or fatty liver content, should be tested specifically in those with SIRD and MOD characteristics. This evidence concerns the gene INS and prediabetes syndrome.